Insiders | Shares | % | Avg Price | Total $ | |
---|---|---|---|---|---|
Buys | 0 | ||||
Sells | 11 | -891 K | 100% | $16.75 | -$14.9 M |
Net | -11 | -891 K | -100% | -$14.9 M |
Name | Relationship | Holdings Value | Past Year Net Change | Change % | Report Date |
---|---|---|---|---|---|
Aladar Szalay | 10%+ Owner | $4.19 M | -$10.6 M | -71.6% | May 13, 2024 |
Qian Zhang | Associate VP, Research | $1.98 M | Feb 17, 2023 | ||
John Thomas | Director | $1.71 M | -$346 K | -16.8% | May 29, 2024 |
Thomas Zindrick | President and CEO, Director | $786 K | -$198 K | -20.1% | May 29, 2024 |
Gabe Woodward | Director | $175 K | Feb 17, 2023 | ||
Lourie S. Zak | Chief Financial Officer | $114 K | May 29, 2024 | ||
Ralph Smalling | Head of Regulatory | $48.8 K | -$22.2 K | -31.3% | May 29, 2024 |
John W. Smither | Director | $48.2 K | -$18.7 K | -27.9% | May 29, 2024 |
Mary Mirabelli | Director | $45.6 K | May 29, 2024 | ||
Sean Ryder | General Counsel | $38.7 K | -$308 K | -88.8% | May 29, 2024 |
James L. Tyree | Director | $35.6 K | -$119 K | -77% | May 29, 2024 |
Yong Yu | VP, Clinical Trial Operations | $9.16 K | -$3.19 M | -99.7% | May 29, 2024 |
Doug Samuelson | Vice President, Finance | -$30.8 K | Sep 11, 2023 | ||
Joseph Cappello | VP, Pharmaceutical Development | -$77.5 K | Sep 11, 2023 | ||
Caroline Jewett | Head of Quality | -$12.2 K | Oct 2, 2023 | ||
Paul Scigalla | Chief Medical Officer | Jan 25, 2023 |
Insider | Class | Transaction | % | Value $ | Price $ | Shares | Shares Owned | Date | Ownership |
---|